Cargando…

Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract

Cervicovaginal fluid has an important function in the homeostasis and immunity of the lower female genital tract. Analysis of the cervicovaginal fluid proteome may therefore yield important information about the pathogenesis of numerous gynecological pathologies. Additionally, cervicovaginal fluid h...

Descripción completa

Detalles Bibliográficos
Autores principales: Zegels, Geert, Van Raemdonck, Geert AA, Tjalma, Wiebren AA, Van Ostade, Xaveer WM
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016264/
https://www.ncbi.nlm.nih.gov/pubmed/21143851
http://dx.doi.org/10.1186/1477-5956-8-63
_version_ 1782195705357533184
author Zegels, Geert
Van Raemdonck, Geert AA
Tjalma, Wiebren AA
Van Ostade, Xaveer WM
author_facet Zegels, Geert
Van Raemdonck, Geert AA
Tjalma, Wiebren AA
Van Ostade, Xaveer WM
author_sort Zegels, Geert
collection PubMed
description Cervicovaginal fluid has an important function in the homeostasis and immunity of the lower female genital tract. Analysis of the cervicovaginal fluid proteome may therefore yield important information about the pathogenesis of numerous gynecological pathologies. Additionally, cervicovaginal fluid has great potential as a source of biomarkers for these conditions. This review provides a detailed discussion about the human cervicovaginal proteome and the proteomics studies performed to characterize this biological fluid. Furthermore, infection-correlated pathological conditions of the female genital tract are discussed for which cervicovaginal fluid has been used in order to identify potential biomarkers. Recent years, numerous studies have analyzed cervicovaginal fluid samples utilizing antibody-based technologies, such as ELISA or Western blotting, to identify biomarkers for preterm birth, premature preterm rupture of membranes, bacterial vaginosis and cervical cancer. The present article will discuss the importance of proteomic technologies as alternative techniques to gain additional meaningful information about these conditions. In addition, the review focuses on recent proteomic studies on cervicovaginal fluid samples for the identification of potential biomarkers. We conclude that the use of proteomic technology for analysis of human cervicovaginal fluid samples is promising and may lead to the discovery of new biomarkers which can improve disease prevention and therapy development.
format Text
id pubmed-3016264
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30162642011-01-06 Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract Zegels, Geert Van Raemdonck, Geert AA Tjalma, Wiebren AA Van Ostade, Xaveer WM Proteome Sci Review Cervicovaginal fluid has an important function in the homeostasis and immunity of the lower female genital tract. Analysis of the cervicovaginal fluid proteome may therefore yield important information about the pathogenesis of numerous gynecological pathologies. Additionally, cervicovaginal fluid has great potential as a source of biomarkers for these conditions. This review provides a detailed discussion about the human cervicovaginal proteome and the proteomics studies performed to characterize this biological fluid. Furthermore, infection-correlated pathological conditions of the female genital tract are discussed for which cervicovaginal fluid has been used in order to identify potential biomarkers. Recent years, numerous studies have analyzed cervicovaginal fluid samples utilizing antibody-based technologies, such as ELISA or Western blotting, to identify biomarkers for preterm birth, premature preterm rupture of membranes, bacterial vaginosis and cervical cancer. The present article will discuss the importance of proteomic technologies as alternative techniques to gain additional meaningful information about these conditions. In addition, the review focuses on recent proteomic studies on cervicovaginal fluid samples for the identification of potential biomarkers. We conclude that the use of proteomic technology for analysis of human cervicovaginal fluid samples is promising and may lead to the discovery of new biomarkers which can improve disease prevention and therapy development. BioMed Central 2010-12-08 /pmc/articles/PMC3016264/ /pubmed/21143851 http://dx.doi.org/10.1186/1477-5956-8-63 Text en Copyright ©2010 Zegels et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Zegels, Geert
Van Raemdonck, Geert AA
Tjalma, Wiebren AA
Van Ostade, Xaveer WM
Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract
title Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract
title_full Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract
title_fullStr Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract
title_full_unstemmed Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract
title_short Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract
title_sort use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016264/
https://www.ncbi.nlm.nih.gov/pubmed/21143851
http://dx.doi.org/10.1186/1477-5956-8-63
work_keys_str_mv AT zegelsgeert useofcervicovaginalfluidfortheidentificationofbiomarkersforpathologiesofthefemalegenitaltract
AT vanraemdonckgeertaa useofcervicovaginalfluidfortheidentificationofbiomarkersforpathologiesofthefemalegenitaltract
AT tjalmawiebrenaa useofcervicovaginalfluidfortheidentificationofbiomarkersforpathologiesofthefemalegenitaltract
AT vanostadexaveerwm useofcervicovaginalfluidfortheidentificationofbiomarkersforpathologiesofthefemalegenitaltract